That this House has considered the impact of NHS workforce levels on cancer patients.
It is a pleasure to serve under your chairship, Ms Hobhouse. I declare an interest as a governor of the Royal Berkshire hospital. Also, a family member has shares in a medical company.
Being a cancer survivor, cancer diagnosis, treatment and outcomes are important to me. I thank the 136 people who responded to my survey ahead of this debate, and the Chamber engagement team for helping to highlight the real experiences of cancer patients across the country. I also thank all the organisations that have helped me and my office to prepare for the debate.
Shortfalls in the NHS workforce are no secret. Consultants, nurses, radiologists and oncologists are all working flat out to deliver care but are being held back by staff shortages, limited equipment, outdated buildings and a lack of training. This is a legacy of the last Conservative Government. The new Labour Government must act swiftly to support our NHS workforce and deliver world-class cancer care.
I welcome the commitment to a new national cancer plan that was confirmed on 4 February 2025—World Cancer Day—after I called for a national cancer plan on 31 October last year. That plan must prioritise early diagnosis and improved treatment. Perhaps it could even be launched on World Cancer Day 2026, which is 4 February.
According to Lilly UK, only one third of NHS staff believe there are enough people for them to perform their roles effectively. The Royal College of Radiologists reports a 29% shortfall in radiologists, or 1,670 consultants, which is set to rise to 39%, or 3,112 consultants, in five years. An extra 346 radiologists are now needed to clear the diagnostic backlog—equivalent to 9% of the current workforce. The Royal College of Pathologists found that 60% of consultants said their departments lack adequate resources, including staff.
Clinical oncology faces a 15% shortfall, forecast to reach 19% by 2029, with smaller cancer centres suffering vacancy rates six times higher than larger ones. In genomics, only 60% of tests are delivered on time, mainly due to a shortage of pathologists. In 2022, NHS England reported a 12% mammographer vacancy rate, rising to 15% in the midlands and south-east, and 36% of the workforce are due to retire within the next 10 to 15 years. Mike Richards’ 2020 review found that histopathology activity had increased by 30% between 2018 and 2019, while consultant numbers rose by just 8%. The gap continues to widen.
The UK also has among the lowest numbers of MRI, CT and PET scanners per million of the population among comparable nations, with just 10 CT scanners, 8.6 MRI units and 0.5 PET scanners per million. Even when equipment exists, staff shortages mean it is often not used. One survey respondent arrived for a CT scan to find no staff available to operate the machine.
In August 2025, only 69% of patients began treatment within 62 days of urgent referral—far below the 85% target, which has not been met since December 2015. That is the fault not of this Government but of the last one, but this Government need to make some improvements.
Early diagnosis is key to survival, yet 73% of hospitals are failing to meet the 62-day target. Between January and July 2025, only 66.7% of breast cancer patients began treatment within 62 days of referral. According to data from Breast Cancer Now, if the 85% target had been met each month, 2,931 more people would have started treatment on time. Even under Labour we are continuing to struggle. The Government are not making enough of a difference yet. But I must say again that the problems in the NHS are down to 14 years of Conservative Governments.
Best practice recommends a triple assessment, a clinical exam, imaging and biopsy in a single appointment, yet between 2020 and 2022 only 68% of people received that, due to staff shortages. The failure to streamline diagnosis creates delays and backlogs. Nearly everyone who is diagnosed with bowel cancer early survives for five years, but only one in 10 survive if they are diagnosed late. Still, just 38% of patients in England are diagnosed at stages 1 or 2. One respondent shared how her daughter, who was diagnosed with stage 4 bowel cancer, waited months to start treatment due to delays caused by workforce issues.
In July 2025, only 50% of lower gastrointestinal cancer patients were treated within 62 days of referral, although 93% began treatment within 31 days of a decision to treat. That shows that the delays occur early in the diagnostic process. At the same time, 91,400 people were waiting for a colonoscopy or a sigmoidoscopy. Around 28% waited for more than six weeks and 13% for more than 13 weeks. The Government must increase endoscopy and pathology capacity, and that requires the improvement of staffing levels.
Less survivable cancers—lung, liver, brain, oesophageal, pancreatic and stomach—are most affected by workforce shortages. Only 35% of pancreatic cancer patients receive treatment within 62 days. Less survivable cancers account for 20% of cases but cause 42% of cancer deaths, with a five-year survival rate of just 16%, compared with 55% in more survivable cancers. A new national cancer plan must include a strategy specifically for less-survivable cancers.
Between 2015 and 2023, one in four leukaemia patients faced avoidable diagnostic delays. A Leukaemia UK survey found that insufficient phlebotomy capacity was the top reason for delays in basic full-blood-count tests—a simple, inexpensive diagnostic tool. Acute myeloid leukaemia patients who faced avoidable delays were 22% more likely to die within a year of diagnosis. The Government should audit and invest in phlebotomy services, as called for by Leukaemia UK and the Royal College of General Practitioners. The Government also need to establish a national register of available phlebotomy sites.
Cancer remains a leading cause of death from disease among teenagers and young adults, but it is too often missed. Around 46.3% of 16 to 24-year-olds saw a GP three or more times before diagnosis, according to the Teenage Cancer Trust. That diagnosis delay is exacerbated by a nationwide decline in GPs, meaning longer waits and reduced access to diagnostic services. The national cancer plan and workforce plan must ensure that all frontline healthcare professionals—from GPs to A&E staff and opticians—are trained to recognise cancer symptoms in young people. Services in deprived areas also need support. Those communities face heavier workloads, greater pressure and less funding. The Government must provide targeted support for those areas.
Forty-three per cent of brain tumour patients saw a healthcare professional three or more times before diagnosis, and 55% of parents said their child’s tumour was misdiagnosed. In 2020, 45% of brain tumours were diagnosed in emergency settings—double the 22.5% for all cancers.
According to the Brain Tumour Charity, shortages of neuroradiologists and limited imaging access, alongside GP training gaps, have caused these delays. GPs should be allowed to request neuroimaging directly for concerning symptoms. For prostate cancer, in July 2025, only 55% of men began treatment within 62 days—a 5% drop since January. Even this year, we are still heading in the wrong direction. Men are waiting weeks or months for MRI and biopsy results due to staff shortages. England also has one of the lowest numbers of radiologists per head of population in Europe, a situation that must be rectified.
Clinical nurse specialists are essential to patient support, yet in 2024, 31% of blood cancer patients did not know who their clinical nurse specialist was, and 22% did not know how to contact them. That information is from Blood Cancer UK. Among secondary breast cancer patients in 2019, 25% had not seen a CNS since diagnosis, and only 65% said their CNS had sufficient time for them. For leukaemia, just 9% were offered a holistic needs assessment, which CNSs help to deliver. The national cancer plan must ensure that every patient has access to a CNS, but instability is worsening.
The Royal College of Radiologists’ 2024 census found that colorectal oncology has the highest locum reliance, at 13%. One in five colorectal consultants will retire within the next five years. How are we going to replace those healthcare professionals? The British Association of Urological Surgeons reports that 12% of consultant roles are unfilled, with a growing reliance on costly locums.
In haematology, the east midlands has twice as many vacancies as filled clinical scientist roles, with 32% of haematology clinicians planning to reduce their working hours. Again, the Royal College of Radiologists reports that the median age of radiologists leaving fell from 56 in 2021 to 49 in 2024, and for clinical oncologists from 59 to 54 in one year. Around 20% of clinical oncology consultants will retire in the next five years.
The NHS is losing staff faster than it can replace them. What will the Government do to replace those doctors before they retire? People with less survivable cancers often have rapid disease progression and experience severe symptoms. Around 70% of pancreatic cancer patients receive no active treatment; many are too unwell or diagnosed too late.
Specialist symptom management and supportive care must be expanded to reduce emergency admissions and improve quality of life, yet the NHS cannot currently deliver this. Less survivable cancers must have their own section in the national cancer plan. Advanced treatments such as CAR T-cell therapy for leukaemia are not available everywhere due to a lack of trained staff and infrastructure, resulting in a postcode lottery for lifesaving treatment. The Government must invest in training, especially in primary care, and increase specialist training places in radiology and oncology, as called for by the Royal College of Radiologists. The Government must also end recruitment freezes. On research, only 12% of brain tumour patients have taken part in a clinical trial, and 42% say they were never informed about opportunities to be part of a trial. Investment is needed in research, nurses, radiographers and infrastructure, as well as in embedding research into routine care and protecting staff time to deliver trials.
The Royal College of Radiologists is clear that delays caused by staffing gaps are endangering patients. Without investment, waiting times will lengthen, treatment delays will worsen and costs will rise. I hope it is clear to all of us that workforce shortfalls are a massive barrier to early diagnosis and effective, timely treatment across all cancers. The Government must increase recruitment, training and retention, support primary care referrals, invest in diagnostic infrastructure and education, guarantee access to clinical nurse specialists and prioritise support for patients with less-survivable cancers. Those steps must underpin the national cancer plan and the 10-year workforce plan. Lives depend upon it.
I remind all Members that they should bob if they wish to speak. The debate will run until 3.10 pm, and I intend to call the Liberal Democrat spokesperson at 2.38 pm.
You will not be surprised to hear, Mrs Hobhouse, that it is a pleasure to serve under you. I thank the hon. Member for Wokingham (Clive Jones) for securing this important debate. I declare an interest: my lovely wife has worked as part of the NHS workforce in Scotland for around 30 years, and on Monday she is due to start a one-year secondment to the Marie Curie hospice in Edinburgh, so I take this opportunity to wish her well. As I have more time to speak debate than expected, let me also take this opportunity to thank all the people in Edinburgh South West who raise money for that hospice, including BobCat Alpacas, which recently raised around £10,000 at its open day.
This morning I met with MacMillan Cancer support, as I am sure other Members did too. I want to recognise its efforts across the UK in supporting people facing a diagnosis, as well as recognising groups in my constituency such as The House of Hope, which supports people with a breast cancer diagnosis. We have to recognise the pressure that NHS staff are under—not just my lovely wife, but staff right across the NHS in the UK, although I will start by talking about England.
The pressure on the staff who are supporting cancer patients in the NHS is why I absolutely welcome the forthcoming workforce plan and the national cancer strategy. I hope they can make a real difference to staff and cancer patients in England. I am proud that it is a Labour Government that are showing real ambition—the word ambition is important here—but I support Cancer Research UK’s ask for a dedicated cancer workforce planning strategy. I also agree with Leukaemia UK that the 10-year workforce plan must enable and support the delivery of the national cancer plan. I am sure that is not a controversial view—it makes absolute sense.
I have been lucky to table a private Member’s Bill on rare cancers, and through that I have met many cancer charities. I have to say that all of them respect the work of the hon. Member for Wokingham—I am trying to find one that does not, but they all do. I recently met with Blood Cancer UK to talk about its work, and it informed me about this debate. I was asked to raise the situation in haematology in England, which is particularly concerning.
It is a pleasure to serve under your chairmanship, Mrs Hobhouse. I congratulate my hon. Friend the Member for Wokingham (Clive Jones) on securing this important debate. It is unusual to be called so quickly; we are often oversubscribed, so it is a pleasure to be able to say something a little more substantive than what I had initially prepared.
I want to talk about the impact on the workforce in my area, Harrogate and Knaresborough, and across the Yorkshire and Humber region. We need a strong and sustainable NHS workforce, which is critical to improving cancer outcomes. There is rising demand: the number of people in Yorkshire receiving urgent checks for cancer has doubled in the past 10 years and is projected to keep rising. Cancer services in our region are consistently failing to meet national targets.
Action is desperately needed to make the NHS a more attractive and sustainable career choice. That includes investing in training, improving retention and prioritising staff wellbeing. One of the biggest frustrations I hear from local staff at our hospital is the inability to even find a place to park at work and the impact that that has on the surrounding area.
I welcome the forthcoming workforce plan. I know that a number of organisations, including Yorkshire Cancer Research, will be keen to submit evidence to ensure that the needs of cancer patients in our region are fully addressed. We need to make sure that staffing levels are delivered and that the support for growing demand is not left behind.
There are a number of gaps in the workforce across my patch. Yorkshire has the lowest rate of clinical and medical oncology consultants of any region in the country, at 5.1 per 100,000 people aged 50 and above, compared with 6.6 nationally and 11.3 in London. The regional shortfall in clinical oncology consultants is 18%, higher than the national average of 15%.
It is a real pleasure, as always, to serve under your chairship, Mrs Hobhouse. I thank the hon. Member for Wokingham (Clive Jones) for raising this matter, which affects constituents in every part of this United Kingdom of Great Britain and Northern Ireland. I always admire the hon. Gentleman because of the personal experiences with cancer that he tells us about. I have heard about them from him personally, but also in this Chamber. His heart is for those with cancer, and those who suffer and need to find a cure. I congratulate him on all he does.
As the hon. Member for Harrogate and Knaresborough (Tom Gordon) mentioned, the Macmillan coffee morning was this morning. Macmillan put forward some recommendations this morning, and I wonder whether the Minister has had an opportunity to have contact with the group. Macmillan is always helpful—it is not here to catch anybody out—and it was putting forward positive ideas on how to do things better. Perhaps the Minister can indicate whether that opportunity has come forward.
In this life, there are not many things that I say I hate—when I use that word, I mean it—but I do hate cancer. I hate the devastating effect it has on people and families. I hate that children suffer and that their parents can only stand by and watch, as happens on many occasions. I hate that children are left motherless or fatherless and that nothing can be done. I hate having to deal with that dreadful disease. But most of all I hate that we cannot cure it—at least, not yet.
One of my requests to the Minister, who is always incredibly helpful, is on research and development. Statistically, one in two people we meet—half the people in this room—will have cancer; 50% will survive, and 50% will not. The research and development is so important for getting to the day when we find a cure. I know the Minister is committed to that, and I hope she can give us some idea what is being done on that.
I know that this subject is important to the hon. Gentleman. Pancreatic Cancer UK is a fantastic charity. Unfortunately, he could not make this year’s Labour party conference in Liverpool, although he is always welcome to attend—Labour MPs go free, so he is welcome to join up. However, Pancreatic Cancer UK was there with scientists who are looking at a new diagnostic tool that, believe it or not, is based on a breath test. They can analyse a small particle in our breath to give an indication of whether there could be something that needs further investigation. That is a great example of how investment can help to save lives while bringing jobs to the UK. I am sure the hon. Gentleman will congratulate Pancreatic Cancer UK on all its work in this field, and on that little piece of progress.
I welcome the hon. Gentleman’s encouraging intervention. That is what it is all about. Of course, I attend my own party’s conference—I am not sure I would attend anyone else’s. Party conferences are a great opportunity to meet groups that are working hard, and they come to our conference too. That breath test is encouraging, and perhaps it will be part of the next stage of curing cancer, and particularly pancreatic cancer.
The target of starting treatment within 62 days of an urgent GP referral is not being met, with only 37% of patients receiving treatment within the critical window—those figures are from 2023. As of September 2023, some 545,000 people in Northern Ireland, which has a population of 1.95 million, were waiting for elective care. My goodness, is that not a scary figure? That issue is not the Minister’s responsibility, but it worries me when I consider it. It is the highest number on record. Waiting times for in-patient admissions and out-patient appointments, including for cancer patients, have increased dramatically since 2020.
There are shortages across multiple disciplines, including paediatricians, administrative support, pathologists, radiologists, chemotherapy nurses and palliative care staff. For example, while the number of clinical radiologists has increased, which is good news, the Royal College of Radiologists estimates that the workforce is still 50% smaller than is needed to meet demand. Yes, there have been advances, but we are not there quite yet. Current staff face extreme workload pressures, leading to a fear of missing early diagnoses, and also burnout for those whose commitment to help their patients is above and beyond what their wage packet might indicate.
We are not coping well. A constituent came to my office to ask why her first smear test results took 16 weeks to come back, and why she had to ring her GP on three occasions to get them. On her behalf, I had to email the doctor’s surgery and the health trust so that the biopsies were taken. It is easy to understand why her anxiety levels were through the roof. She now has to wait a further six to eight weeks to see whether she needs treatment. My goodness, it is little wonder that people are so worried, anxious and stressed.
It is a pleasure to serve under your chairship, Mrs Hobhouse. I thank my hon. Friend the Member for Wokingham (Clive Jones) for securing this important debate highlighting the issue of staff shortages and the impact on cancer patients and the outcomes that they achieve.
Cancer should be a top priority for any Government, and the UK—with its historically thriving life sciences sector—could and should be a global leader in cancer research and outcomes. Sadly, at the moment, that is not necessarily the case. The last Conservative Government broke their promise on a 10-year cancer plan that would have made a real difference to patients. We must put an end to the tragedy of people losing their lives because cancer treatment takes too long to start. No one should be unable to receive treatment because there is not enough equipment or sufficient staff to properly support them. It is a scandal that so many people live in treatment deserts and are forced to take incredibly long journeys for treatment, often after weeks of waiting for that treatment to begin.
In that context, the introduction of a national cancer strategy is incredibly welcome. It should help to boost cancer survival rates. I am very proud that my hon. Friend the Member for Wokingham—who, as we have heard, is a widely respected cancer campaigner—has helped to secure a commitment from the Government to introduce such a plan. It is really important that when this plan comes, it is meaningful. The Government should take bold action: ensuring that every patient starts treatment for cancer within 62 days of their urgent referral, recruiting the cancer specialists we need, and replacing ancient machines and delivering new ones.
The situation on the ground at the moment is not very good. My constituents in North Shropshire have had to deal with some of the worst backlogs and performance in England for years. One told me that they waited almost a year before their treatment began—that is simply not okay. Look at the target of treatment starting within 62 days of urgent referral: Shrewsbury and Telford Hospital NHS Trust only achieved 68.8% for the month of August this year, compared with a target of 85%. That, however, is a significant improvement on its previous situation, with performance against that target improving by more than 15.4% over the past year. That progress is welcome, obviously. I am optimistic that it will be sustained and I commend and thank the tireless work of staff across the trust in driving those improvements.
It is a pleasure to serve under your chairmanship this afternoon, Mrs Hobhouse. I congratulate the hon. Member for Wokingham (Clive Jones) on securing this debate.
Across the United Kingdom, an estimated 3.5 million people are living with cancer. We all know a friend, family member or co-worker who has battled the disease, and, sadly, we also all know of somebody whose life was cut short by it. Our country faces an ageing population, which will mean more cancer cases in the years to come; the longer we live, the greater the risk.
Troublingly, cancer rates are also rising among those in their 20s, 30s and 40s, so getting cancer care right today will mean the difference between lives saved and lives lost tomorrow. We know that the NHS cannot deliver timely, effective cancer care without the workforce trained to provide it. We owe it to patients fighting cancer today—and the 50% of us who will face cancer tomorrow—to fix the situation.
NHS staff are carrying out more cancer checks than ever before: more than 3 million a year in 2024, compared with less than half that a decade ago. In the last five years, we have also benefited from an increase in the number of clinical and medical oncologists in the NHS as well as of clinical radiology staff. Sadly, however, demand for services is fast outpacing the supply of staff, putting teams under immense pressure. Last year, more than 74,000 people in England were not treated on time for cancer, increasing their risk from the disease.
Formal training for medical staff begins at university. The previous Government increased the number of places at medical school, and increased the number of medical schools by building five new ones. This Government have said that they will increase the number of medical school places. Could the Minister confirm the places that they will fund for next September, bearing in mind that the application date has now passed?
It is a pleasure to serve under your chairship, Mrs Hobhouse. I thank the hon. Member for Wokingham (Clive Jones) for securing the debate, and for getting through it—I hope he is well. I thank other hon. Members for their contributions. As others have noted, I am aware of the work that the hon. Gentleman has done, using his experience for good, on access to primary care, radiotherapy and cancer. He has campaigned on behalf of his constituents in Wokingham and people across the country, as the hon. Member for Strangford (Jim Shannon) said. He has been a keen advocate for the NHS workforce’s importance to delivering the health services we need.
I thank the wife of my hon. Friend the Member for Edinburgh South West (Dr Arthur) for her service and wish her well in her new role at the hospice. It is really good to have a voice from Scotland in these debates. My hon. Friend spoke about the shocking and deeply concerning waiting times that our friends and families in Scotland are experiencing. The Scottish people will have a chance to start reversing the situation next May. I hope they take that opportunity, and I look forward to joining my hon. Friend to try to make that happen.
I have my green jacket on, but I am sorry that I could not join today’s Macmillan coffee morning, which the hon. Member for Strangford mentioned. The Under-Secretary of State for Health and Social Care, my hon. Friend the Member for West Lancashire (Ashley Dalton), is working very closely with Macmillan and many other cancer charities as she develops the cancer plan. She is in good contact with them; they do great work, and we will ensure that we continue to talk through their many asks of the Government as she develops the workforce plan.
As many hon. Members said, half of us will have a cancer diagnosis in our lifetime. The health team has certainly taken our full part in that, as 50% of us have had a cancer diagnosis. Some of us are still undergoing treatment. Although more than three quarters of all people diagnosed with cancer in the UK are 60 and over—as hon. Members said, the population is ageing—I decided to get mine at 59. My hon. Friend the Member for West Lancashire is also younger than 60, and the Secretary of State would not forgive me for not reminding everybody that he is only in his early 40s. We make the point well: as other Members said, that although incidence will increase as a result of our ageing population, cancer can strike anybody at any age.
I thank the Minister for giving way. As ever, she is most generous with her time. She has outlined the positive steps that the Government are taking to address the workforce challenge. Could she elaborate on the points I made about the inequalities between the north and the south in the NHS and the cancer workforce?
20 of 27 shown
Blood cancer accounts for a third of cancer deaths in the UK, but Blood Cancer UK says that treatment is continuously impacted by staffing shortages. It told me about how one patient shared that they had had seven different consultants in the past five years, and they were terrified about not knowing who to contact if their symptoms got worse—not a great situation. Figures from Blood Cancer UK show that in south-east England the vacancies for advanced haematologist nurse practitioner roles are 111% greater than the numbers in post, so there are more vacancies than people in post. That impacts both patients and the staff in post, for whom it must be incredibly stressful.
I hope that in the upcoming workforce plan the Government recognise the central role that haematologists play in cancer care. We have to recognise that having a haematology workforce that is staffed to the correct level has benefits well beyond cancer care. I hope the Government will put measures in place to address the shortfalls. As the hon. Member for Wokingham said, steps to drive up the recruitment and retention of clinical nurses will be crucial.
Let me turn to Scotland, where of course health is devolved. Back in August, I welcomed the news that the risk of dying from cancer in Scotland had reached a record low, which is a fantastic landmark. However, the data only covered the period up to 2022. In 2025, cancer waiting times in Scotland have never been worse. The Royal College of Radiologists has indicated that, without addressing staffing, the situation will only get even worse. Right now, that seems unthinkable. Data shows that there is a 25% shortage of radiologists—again, a discipline that has benefits well beyond cancer care—and a 19% shortage of oncologists. One in five consultant haematologists are near retirement, and there is low recruitment into the sector, so patient groups are very concerned about what that means for the future.
The Scottish Government say that they are investing in cancer treatment, yet patients have been failed and left without effective care—that is the reality when we look beyond the press releases. Hon. Members do not have to take my word for it: Dr Iain Kennedy, who chairs the Scottish council of the British Medical Association, said that Scotland is now divided between people who can afford to go private and those forced to “languish” on NHS waiting lists. We often think about people going private for cosmetic work, or perhaps even hip surgery, but if people in Scotland, or anywhere, are going private for cancer care, that is a real inequality.
Cancer mortality rates for the poorest in Scotland are 78% higher than those for the richest. That shames me as a Scot, and I want change. The Scottish Government are failing to address the very low staffing levels that feed these issues. There is no workforce plan. The UK Government are currently looking at one, but there is none in Scotland. They actually had one, which expired in March this year. I checked it this morning, and it did not even mention cancer care. Perhaps that is why we have the worst cancer waiting times on record.
While the UK Government are taking action through the workforce plan, which I look forward to hearing more about from the Minister, the situation in Scotland looks like it can only get worse. We will have an election for the Holyrood Parliament next year. I hope that cancer care is a key part of the discussion, because it is in real crisis in Scotland. The country needs change. Our NHS needs change.
As has been mentioned, we are also experiencing shortfalls and shortages in services and support staff, such as clinical radiologists. There is considerable concern, with 79% of clinical directors across Yorkshire and the Humber—the highest proportion in England—saying there are insufficient radiologists to deliver safe and effective care. The current shortfall is 33%, and the figure is projected to rise to 41% by 2029, placing Yorkshire among the worst-affected regions.
We are also experiencing the complexity of an ageing workforce. Yorkshire and the Humber has the joint highest proportion of clinical radiologist consultants expected to retire over the next five years—22%, compared with 20% in the rest of England—and a lower than average forecast of growth in that role.
I hear from local people that some of the barriers they face to accessing cancer pathways are at the point of general practice. Difficult conversations often occur at the GP. Timely access is crucial, yet we have significant variation in GP availability across the country and even across Yorkshire. For example, in Kingston upon Hull East, each GP services 3,664 patients, which is more than double the number in Sheffield South East. With one in two cancers diagnosed late, improving access to GPs is vital for early detection and therefore better outcomes. I have received a number of emails from people completing their training in the NHS as GPs and doctors on their concerns about their ability to find work. I hope the Minister—and, going forward, the workforce plan—can address that.
Research-active hospitals deliver better survival outcomes, even for patients who are not directly involved in trials. For example, bowel cancer patients treated in NHS hospital trusts with high levels of research participation had improved survival outcomes in the first year after diagnosis. What worries me is that across Yorkshire we saw a 25% decline in clinical academic posts between 2012 and 2022, which was four times higher than the national decline.
When we talk about the NHS workforce and its impact on cancer, it is important to acknowledge that the charity sector often supplements the work our NHS does. In my constituency, we have Harrogate Hospital and Community Charity, which is celebrating its 30th anniversary this year. I was pleased to run the Paris and London marathons to raise money for it earlier this year. It is a fantastic organisation that does amazing work on the ground, going above and beyond what the NHS can provide for people with a range of health issues. Last year, I was able to attend a Macmillan coffee morning at the Sir Robert Ogden Macmillan Centre, and today I attended the Macmillan coffee morning here in Parliament.
Broadly speaking, the feedback I hear from anyone accessing cancer facilities and services in my patch is that our local provision is fantastic. One constituent, John Fox, who has recently gone through those services, described an amazing team that was supportive, caring and helpful. It is important, while we talk about the issues that we are facing, to highlight some of the positives and the good experiences that people have.
In summary, what I would like to see going forward, and what I hope the Minister might be able to comment on, is how we will better invest in training, recruitment and retention of staff in the NHS and how we will address regional inequalities and support research capacity.
Each of us in this place will have been touched by cancer. I think of my own dad. My dad has been dead now for 10 years, but he was a cancer survivor on three occasions. He put that down—as I would as well—to the skill of the surgeon, the care of the nurses and the prayers of God’s people, which helped him get out the other side.
We can argue about microwaves, about preservatives in food and about genetic or carcinogenic factors, but this debate is about ensuring that NHS workforce levels enable every sufferer to have the best chance possible to fight cancer. As the hon. Member for Wokingham and others who have spoken have said, we are not there just yet. There are insufficient NHS workforce levels in Northern Ireland—I know that that is not the Minister’s responsibility, but I want to give a flavour. Things are not that different there; what happens in Northern Ireland happens in England, Wales and Scotland. If cancer patients have delayed diagnoses and treatments, that can lead to potentially life-threatening consequences and increased anxiety. First, people are anxious about their health, and then they are anxious about how to pay the bills: “Do I get benefits? Can I get some help to get me through? Can I get my mortgage extended?” People have to face up to really life-altering circumstances, and unmet support needs as well.
Then we have the shortages in key roles, such as specialist nurses, radiologists and surgeons. Unfortunately, that means that treatment targets are frequently missed and patients do not receive the full support they require during and after treatment. The situation is worsened by growing waiting lists, increased workloads for existing staff and a lack of resources for both acute and community-based care.
The hon. Member for Wokingham spoke about pancreatic cancer. Many cancers are devastating, but pancreatic cancer is one of the worst. In the last 10 days, a young lady from Greyabbey, a village close to where I live, died of pancreatic cancer. She was 31 years of age, with a five-year-old son and a partner. I remember others. When pancreatic cancer is diagnosed, it is too late, because it has already taken effect and the body is already succumbing to that terrible cancer. That is why I go back to research and development. Will we find the cure for pancreatic cancer someday? Will we be able to diagnose it at an earlier stage so that we can give the treatment and help that are needed?
The fact is that waiting times affect the mental health of even the young and the fit. If we are to give people the tools they need to win their health battle, as we need to, it begins with efficient diagnosis and treatment. We are not getting it right, and that is a fact. We can do better. Our constituents believe they are losing the battle before it truly begins, so what do we need to do? We need to bring our workforce up to par by ensuring that money in the NHS is spent appropriately and is not, to use an Ulster Scots word, frittered away.
I make a plea to the Minister for more research. I really believe that what we spend on research will be for the future and finding all the cures. If we go back a few years, only one in three people survived cancer; now it is one in two. That is an advance, and perhaps the day is coming when everyone can be in that place. I think of Queen’s University Belfast as one example. Its partnerships with medical companies to find cures are incredible, and those that it has found through its research are some of the best in the United Kingdom, if not the world.
To conclude, our NHS staff are second to none, but at times they seem to be working with one hand tied behind their backs, and that must cease. We must ensure we have sufficient funding to free them up to do the job and to fight cancer throughout this great United Kingdom of Great Britain and Northern Ireland—always better together.
Staffing levels, especially for radiologists doing diagnostic scans, have been a large part of the problem in Shrewsbury and Telford. Outsourcing the interpretation of those scans has led to a dramatic improvement in the speed at which the results come back and demonstrates the importance of having enough skilled staff and the speedy diagnostics that can help with early treatment commencing. That issue is particularly severe in rural areas. I hope that the workforce plan, which will go with the cancer strategy, will address that. BMJ Group research found that every four-week delay to starting cancer treatment is associated with a 10% decrease in cancer survival. Constituents such as mine, who have had horrendous waits for treatment, are bearing the lethal brunt of delays.
NHS workforce statistics show that between June 2020 and June 2025, the number of full-time-equivalent cancer specialists has risen: by 32% for clinical oncologists, 48% for medical oncologists and 27% for the clinical radiology workforce. Clearly, those statistics are welcome. However, analysis from the Royal College of Radiologists argues that the increase in workforce capacity has not kept pace with the ever-growing demand for cancer services, which is inevitable in an ageing population with poor health.
In 2024, the Royal College of Radiologists estimated that the clinical oncology workforce was about 15% smaller than required to meet demand, and projected that that shortfall would rise to 19% by 2029. It also reported that, among the 50 cancer centres surveyed in England in 2024, 76% of heads expressed concerns about patient safety due to workforce shortages.
We also cannot ignore the reality of working conditions in our NHS and their impacts on staff retention. The previous Conservative Government left our NHS under unbearable strain, with professionals working under intense pressure in crumbling hospitals and often without the resources they needed, rather than in safe clinical settings. That does not help the retention of a highly skilled and experienced workforce.
There are also woeful shortages of specialist training places, meaning that we do not have the cancer specialists we need. At the same time, there is rising doctor unemployment despite growing need for their services. It is a damning indictment of the Conservatives’ mismanagement and failure to plan the workforce. A workforce plan for the NHS—including a workforce plan to support the cancer strategy—is imperative, and must address the issues of retention and career progression for doctors, nurses and other skilled staff across all specialisms.
While routine NHS workforce statistics are not available for nurses working in cancer specialities, a nursing fill-rate dataset obtained by FactCheck for “Channel 4 News” showed that a third of acute trusts in England were missing at least 10% of their planned nurses across haematology and oncology wards, based on monthly average data between January 2023 and November 2024. That is why the Liberal Democrats are pressing for more cancer nurses—so that every patient has a dedicated specialist nurse supporting them throughout their treatment—and for expanded community nursing.
We have also been campaigning for the UK to lead the world in cancer research through new funding and the waiving of burdensome fees and bureaucracy for international researchers. We would set up a dedicated fellowship scheme for US cancer scientists, who have seen their funding gutted by President Trump.
Without, for example, sufficient radiographers, specialist nurses and diagnostic equipment, even the most promising screening initiatives introduced here risk being delayed or underutilised. The Government need to commit to the funding of early screening programmes, and to training and retaining the workforce required to deliver them. A comprehensive, well-supported roll-out would allow thousands of people at risk to be diagnosed at a much earlier stage, when treatment is far more effective and survival rates are significantly higher.
The national cancer plan provides a huge opportunity for the Government to turn cancer care around in this country and deliver world-class care for every community. I look forward to seeing them deliver that plan, and ensure that it is deliverable through an associated workforce plan, at the soonest opportunity.
The next step, postgraduate training, faces challenges too. The previous Government, as I said, increased medical school places. They also removed the resident labour market test because of the shortage of doctors. The Secretary of State appeared to understand back in Easter the effect that that was going to start to have, as the newly trained doctors came through their postgraduate training.
Over the last two years, the number of international medical graduates applying for training posts has also increased dramatically. The application ratio for postgraduate training posts has gone up substantially and there is a risk that some junior doctors will not get a job. There is also a risk that international medical graduates who get more of the places will return to their country of origin after they have completed training, so we will have unemployed British trainees and doctors who return after training, leaving us with a shortage of consultants in a few years’ time. That issue has been highlighted by the British Medical Association, of which I am a member. Sadly, it has announced that doctors will go on strike from 14 to 19 November this year, partly as a result of pay and partly as a result of job shortages.
The Secretary of State was vociferous in his criticisms of the previous Government when doctors went on strike. What will he and the Minister do to get the doctors back to work? Cancer treatment requires surgery, oncology, haematology, radiology, pathology and geneticists—every specialty across the NHS, including, sadly, paediatrics and sometimes even neonatologists.
There are also challenges across the nursing sector. We saw nurses this year coming out of nursing college with qualifications, but without the posts to go to. There is also a need for other allied health professionals—pharmacists, radiologists, laboratory staff, mammographers and research assistants. Will the workforce plan reflect this? When will it be published? Will it make projections about the population with cancer and will the Government publish those, too? The Government committed to more MRIs and CT scanners. How many new ones have they got in place? How well are they progressing with their targets?
We have heard about the importance of research today. Scientists are a key part of our cancer workforce. We heard yesterday in the Chamber about the challenges that the life sciences sector is facing. The £1 billion investment from Merck for King’s Cross has been shelved. The more than £200 million investment from AstraZeneca in Speke, near Liverpool, has also been shelved, and other investments are paused or mothballed. The industry is talking about poor Government engagement, employment regulations, increased employment taxes such as national insurance, and how they are increasing the voluntary scheme for branded medicines pricing and access payment rate.
What are the Government going to do to ensure that we have research in this country? Research is a real success. We have the best scientists in the world. We have cutting-edge treatment, trial drugs and novel approaches. Those are all more accessible earlier if they are done in the UK. They also provide good jobs for the British workforce. What work is the Minister doing with the Department for Science, Innovation and Technology team? What representation is she making to the Treasury to ensure that supporting research is part of the Government’s actions as well as messaging? Will the supporting research be part of the cancer plan? What support is the Minister giving to rare cancers, particularly those that are particularly lethal such as pancreatic cancer? What about brain tumours, where survival has shown little or no improvement? What focus will the cancer plan have on those?
I sat on the Rare Cancers Bill Committee. The rare diseases framework points out that one in 17 of us will get a rare disease during our lifetime. The current framework initiated by the last Government runs out in around three months’ time. Do the Government plan to replace it? If so, what with and when?
Sadly, as I said earlier, children and teenagers—young people—also get cancer, and they have particular needs as they go through puberty and young adulthood. The workforce therefore has to have particular strengths because of the work involved. I commend the work of the Teenage Cancer Trust and the work that my hon. Friend the Member for Gosport (Dame Caroline Dinenage) is doing. Can the Minister confirm that young people’s and children’s cancer will form an important part of the cancer plan?
Computer scientists will also be key to the cancer workforce. We have heard about the importance of AI. Computers can already identify skin cancer from benign lesions in many cases. The Health and Social Care Select Committee, which I was part of in the last Parliament, visited Stanford in California. We saw how AI was being used to look at mammograms and how, rather than using two doctors, they used one doctor and an AI computer. That was better than either two computers or two clinicians. What is the Minister doing to ensure that, from early education in schools, we are teaching the right skills to develop the right workforce for the AI of the future?
We are getting better at treating cancer, so thankfully there is life after cancer, but post-cancer care is important too. Some people live with things such as lymphoedema, amputations and stomas as a result of their cancer treatment. What focus does the Minister expect there to be in the workforce plan and cancer plan on those issues?
Palliative care is important for those who cannot be treated successfully and whose cancer cannot be cured, but hospices are in crisis across the country. The Government have given extra money for capital, and some for children, which is of course welcome, but hospices across the country are facing huge costs, particularly from the national insurance measures in the last Budget, and neither fund will cover that for adult hospices. Right across the country, we hear about adult hospices that are closing beds. What will the Minister do about that in her plan? How does she expect us to decide on the assisted suicide Bill when palliative care is facing such difficulty? What about the mental health workforce? It is important that people are supported through their cancer journey.
We had the 10-year health plan, with which came the promise of a workforce plan and a national cancer plan, but across the country the British people are waiting. They watch the Labour Government crafting glossy catalogues of intent but failing to deliver for our NHS. The time for planning and prevarication is over. I look forward to the Minister’s response.
Diagnosing and treating cancer is a growing part of NHS elective activity, and responding to demand in a way that best suits patients is crucial. That includes the issues that the hon. Members for Wokingham and for Harrogate and Knaresborough (Tom Gordon) raised about the variability we often see even in a small geographical patch, and certainly between different cancers. The hon. Member for Wokingham talked about clinical nurse specialists. Mine were absolutely fantastic, and I did know who they were. The statistics he outlined are deeply concerning, so those points were very well made. Our mission to tackle cancer and the other biggest killers is underpinned by the 10-year health plan published earlier this year, focusing on those three shifts: from hospital to community, from analogue to digital, and from sickness to prevention.
On the workforce plan, we know that we need an effective and sustainable workforce to deliver better outcomes for everyone, including those with cancer. In the 10-year health plan, we set out that, to deliver a workforce fit for the future, we need a new, sustainable approach to workforce planning. Our 10-year workforce plan will be different. It will set out how we will create a workforce ready to deliver a transformed service for patients when and where they need it, with more empowered, flexible and fulfilled staff.
Since we launched our call for evidence on 26 September, we have been struck by the huge enthusiasm of staff, the sector, stakeholders and colleagues in sharing their thoughts and ideas with us. Many have said that they would like more time to have those conversations, to test ideas and to work together to deliver a truly reformed service. I am grateful to them for raising that, and it is why we have made the decision to give more time to that process. We will now publish the plan in the spring of 2026. A spring publication will allow us to have more detailed discussions with partners, hon. Members and other stakeholders, not just to listen but to work in a truly joined-up way to deliver for staff and patients.
The shadow Minister helpfully outlined all the decisions that were made by her Government over the last few years—decisions that essentially led to many of the workforce problems we now have. We are trying to resolve those problems, and we will. She informed the House that the resident doctors committee has now decided to go on strike again, which is, of course, deeply disappointing. It will be damaging for the work we want to do, and we urge it not to go ahead. However, we will continue to commit to ensuring that the workforce is fit for purpose, including to diagnose and treat cancer. We will progress with the work that we have already started.
In July 2025, there were over 5% more staff in the key cancer professions of clinical oncology, gastroenterology, medical oncology, histopathology, clinical radiology and diagnostic and therapeutic radiography than in July 2024. There were also more doctors working in clinical oncology and more radiology doctors, compared with last year.
My hon. Friend the Member for Edinburgh South West asked particularly about haematology. NHS England has invested in expanding specialty training posts in high-demand disciplines, including haematology, and is supporting local systems to retain and develop multidisciplinary teams. That includes increased medical training posts in haematology, and enhancing the scientific workforce supply through other initiatives.
We have also ensured that the cancer-facing workforce are put on a more stable footing to ensure they have the stability they need to continue to provide the care that patients need. In 2025, we provided grant funding to the Royal College of Radiologists to encourage foundation and internal medicine trainees to specialise in clinical oncology. That work is currently under way and involves a series of webinars as well as targeted engagement. In 2024-25, around 8,000 people received training either to enter the cancer and diagnostic workforce or to develop in their roles. As part of that, more than 1,600 people were on apprenticeship courses, with more than 270 additional medical specialty training places funded. More than 1,000 clinical nurse specialist grants were made available to new and aspiring CNS workers, and it is a really valuable service.